Gkalpakiotis, Spyridon http://orcid.org/0000-0002-6956-5961
Kojanová, Martina
Fialová, Jorga
Cetkovská, Petra
Vašků, Vladimír
Vantuchová, Yvetta
Machovcová, Alena
Gkalpakioti, Petra
Hrdá, Pavla
Arenberger, Petr
Funding for this research was provided by:
LEO Pharma
Article History
Received: 27 September 2023
Accepted: 31 October 2023
First Online: 30 November 2023
Declarations
:
: Spyridon Gkalpakiotis, Martina Kojanová, Jorga Fialová, Vladimír Vašků, Petra Gkalpakioti, Petra Cetkovská, Alena Machovcová, Yvetta Vantuchová and Petr Arenberger have served as consultants, speakers, or investigators for Abbvie, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi and UCB. Pavla Hrda is an employee of LEO Pharma.
: The study was conducted in accordance with the Helsinki Declaration of 1964 and all subsequent amendments, and all patients provided written informed consent. Patient-level data used for this analysis were de-identified. The study was approved by ethical committees of the appointed Institutions (Královské Vinohrady University Hospital, General University Hospital in Prague, St. Anne’s University Hospital Brno, University Hospital in Pilsen, and Motol University Hospital). The study was officially reported to the State Institute for Drug Control, Czech Republic, under the following identification number: 1903110001.